Pfizer’s Turnaround is Gaining Traction, but Can New Products Offset its Patent Cliff?

Pfizer (PFE) and Gilead (GILD) are compared on growth prospects. Pfizer's non-COVID revenue grew 5%, with key drugs like Padcev and Vyndaqel showing gains. Gilead's non-Veklury sales rose 10%, driven by HIV and oncology drugs. Both companies adjusted 2026 forecasts, with Gilead raising its outlook.

Pfizer (PFE) shares dropped 3% on Wednesday despite FDA approval for Ibrance in a new breast cancer treatment, as investors reacted to a failed lung cancer trial. Ibrance's approval is based on a trial showing a 24% reduction in cancer progression or death. PFE stock has fallen 5% year-to-date.

Pfizer (PFE) agreed to a confidential settlement program for 6,289 federal intracranial meningioma lawsuits related to Depo-Provera, with estimated payouts potentially exceeding $1.20 billion. The settlement clarifies legal exposure but does not alter near-term catalysts or long-term risks like pricing pressure. Pfizer projects $54.9 billion revenue and $9.2 billion earnings by 2029, with analysts offering varying outlooks.

Pfizer (PFE) stock has risen 20.5% in the past year, despite flat revenue. The company faces a patent cliff, with $14B-$15B in revenue at risk, but new drugs like Padcev and NURTEC generated $3.2B in Q2 2026. Pfizer raised its 2026 revenue guidance midpoint by $500M, despite cutting COVID revenue expectations. The company aims for high single-digit revenue growth post-2028, with key trial results pending.

Pfizer (PFE) shares fell 2% after reporting mixed results from a late-stage trial of sigvotatug vedotin for non-small cell lung cancer. The drug did not meet the primary endpoint of overall survival in the overall population but showed positive trends in a key subgroup. The stock closed at $25.08 and dropped to $24.71 after hours.

Pfizer and Valneva said the European Medicines Agency validated their marketing authorization application for PF-07307405, a 6-valent OspA-based Lyme disease vaccine candidate. The filing is supported by phase 3 VALOR results showing over 70% efficacy in 9,437 participants aged 5+. No safety concerns were reported.